Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials
European Journal of Cancer · 2024-05 · 202 · 114022
DOI: 10.1016/j.ejca.2024.114022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-05. Verfasst von Vadim Lesan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Department, Saarland University Hospital, Kirrberger Street 100, 66421, Homburg, Germany. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Kaplan-Meier analysis hinges on the assumption that patients who are censored- lost to follow-up, or only recently enrolled on the study- are no different, on average, than patients who are followed. As such, censoring these patients- omitting their future information and taking the average of those who were followed- should not dramatically change the overall estimate. Yet, in a recent clinical trial, two sets of censoring rules- one favored by trialists and one favored by the US Food and Drug Administration- were applied to a progression-free survival (PFS) estimate. In response, the PFS estimate changed dramatically, increasing the median in the experimental arm from 32 to 43 months, while the control arm was essentially unchanged. In this commentary, we explore the reasons why PFS changed so dramatically. We provide a broad overview of censoring in oncology clinical trials, and suggestions to ensure that PFS is a more reliable endpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Oncology Department, Saarland University Hospital, Kirrberger Street 100, 66421, Homburg, Germany.
- Oncology Service, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205, Geneva, Switzerland.
- Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA. Electronic address: vinayak.prasad@ucsf.edu.
Förderung
- Arnold Ventures
Zitieren
APA
Lesan, V., Olivier, T., & Prasad, V. (2024). Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer, 202, 114022. https://doi.org/10.1016/j.ejca.2024.114022
Vancouver
Lesan V, Olivier T, Prasad V. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer. 2024;202:114022. doi:10.1016/j.ejca.2024.114022
BibTeX
@article{Lesan2024,
author = {Lesan, Vadim and Olivier, Timothée and Prasad, Vinay},
title = {Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials},
journal = {European Journal of Cancer},
year = {2024},
volume = {202},
pages = {114022},
doi = {10.1016/j.ejca.2024.114022}
}
EUVIMED